Tan Jerry, Miklas Maegan
Windsor Clinical Research Inc., Windsor, ON, Canada
Schulich School of Medicine and Dentistry, Western University, Windsor Campus, ON, Canada
Skin Therapy Lett. 2020 Mar;25(2):1-2.
Trifarotene 50 μg/g cream is a fourth generation topical retinoid with retinoic acid receptor gamma selectivity. It was recently approved by the US FDA and Health Canada for the topical treatment of facial and truncal acne for those aged 9 and older based on two identically designed phase 3 trials demonstrating superiority in lesion count reduction and global acne improvement compared to vehicle. These studies and a 1 year study also demonstrated safety and tolerability with cutaneous adverse events developing in an anticipated timeframe (1 week) for the face. These were of lesser degree and tended to develop later at the trunk. Future studies will be required to evaluate the comparative efficacy of trifarotene 50 μg/g cream against other treatments for acne.
50μg/g的曲法罗汀乳膏是一种具有γ-视黄酸受体选择性的第四代外用维甲酸类药物。基于两项设计相同的3期试验表明，与赋形剂相比，其在减少皮损数量和整体改善痤疮方面具有优势，该药物最近获得了美国食品药品监督管理局（FDA）和加拿大卫生部的批准，用于9岁及以上人群面部和躯干痤疮的局部治疗。这些研究以及一项为期1年的研究还证明了其安全性和耐受性，面部皮肤不良事件在预期时间（1周）内出现。这些不良事件程度较轻，且在躯干部位出现的时间往往较晚。未来需要开展研究以评估50μg/g曲法罗汀乳膏与其他痤疮治疗方法相比的疗效。
